Cipla Limited has announced its unaudited consolidated financial results for quarter ended September 30, 2018.

Key highlights of the quarter are:

• R&D investments at approximately INR 316cr or approximately 8% of sales
• Growth in private market [non-tender] segments continues strong across India, the US, South Africa and other emerging markets
• US business sales trajectory improves with 12% YoY growth driven by contribution from new launches. 7 new approvals in the quarter with multiple limited competition assets getting launched
• Inspection at Goa plant concludes with minor procedural observations

In India, as per IQVIA (IMS) Q2’18, Cipla continued its outperformance growing by 14%

Performance in key therapeutic areas as follows:

• Cipla gained one Rank in Cardiology and now stands at 4th position growing 500bps higher than market at 19%
• Continued leadership position in Respiratory growing at 23%. Cipla’s flagship
  inhalation awareness campaign “Berok Zindagi’on a good start
• Urology maintained its leadership position with over 15% market share

“We had a modest quarter but maintained a strong performance in our private market segment across geographies. I am pleased to see that our limited competition assets in the
US are ramping up to drive quarter on quarter growth. We also recently announced the approval of Metoprolol, another limited competition asset. As we enter the second half of this fiscal, multiple headwinds are likely to impact our reported performance. Having said that, we are focusing on positioning our businesses for long term growth," said Umang Vohra, MD and Global CEO, Cipla Ltd.